Ribosome inactivating proteins: current status and biomedical applications.

Munish Puri, Inderdeep Kaur, Matthew Perugini, Raghbir Gupta

    Research output: Contribution to journalReview articlepeer-review

    100 Citations (Scopus)

    Abstract

    Ribosome-inactivating proteins (RIPs) are mainly present in plants and function to inhibit protein synthesis through the removal of adenine residues from eukaryotic ribosomal RNA (rRNA). They are broadly classified into two groups: type I and type II. Type I RIPs are a diverse family of proteins comprising a single polypeptide chain, whereas type II RIPs are heterodimeric glycoproteins comprising an A-chain (functionally equivalent to a type I RIP) linked via a disulphide bond to a B chain, mediating cell entry. In this review, we describe common type I and type II RIPs, their diverse biological functions, mechanism of cell entry, stability in plasma and antigenicity. We end with a discussion of promising applications for RIPs in biomedicine.

    Original languageEnglish
    Pages (from-to)774-783
    Number of pages10
    JournalDrug Discovery Today
    Volume17
    Issue number13-14
    DOIs
    Publication statusPublished - Jul 2012

    Fingerprint Dive into the research topics of 'Ribosome inactivating proteins: current status and biomedical applications.'. Together they form a unique fingerprint.

    Cite this